|
Clinico-pathological characteristics of the patients |
|||
| analyzed |
|||
| Patients characteristics |
all trial patients B 1/2 (n = 1399) |
NHL patients (n = 311) |
DLBCL patients (n = 205) |
|
|
|||
| Age Median; yr (range) 75) |
60 (18–75) |
62 (23–75) |
61 (23–75) |
| Sex |
|||
| male |
789 (56%) |
175 (56%) |
115 (56%) |
| female |
610 (44%) |
136 (44%) |
90 (44%) |
| International Prognostic Index (IPI) |
|||
| Low (0,1) |
840 (60%) |
176 (57%) |
118 (58%) |
| Low intermediate (2) |
250 (18%) |
62 (20%) |
42 (20%) |
| High intermediate (3) |
170 (12%) |
46 (15%) |
31 (15%) |
| High (4,5) |
139 (10%) |
27 (9%) |
14 (7%) |
| Risk Age |
|||
| Age ≤ 60 yrs |
710 (51%) |
143 (46%) |
98 (48%) |
| Age > 60 yrs |
689 (49%) |
168 (54%) |
107(52%) |
| Risk extranodal involvement |
|||
| ≤ 1 ex. involvement |
1123 (80%) |
254 (82%) |
174(85%) |
| > 1 ex. involvement |
276 (20%) |
57 (18%) |
31(15%) |
| Risk ECOG |
|||
| ECOG 0,1 |
1236 (88%) |
273 (88%) |
178(87%) |
| ECOG 2–4 |
163 (12%) |
38 (12%) |
27(13%) |
| Risk Stage |
|||
| Stage I, II |
832 (59%) |
191 (61%) |
134(65%) |
| Stage III-IV |
567 (41%) |
120 (39%) |
71(35%) |
| Risk LDH |
|||
| LDH ≤ ONW |
1083 (77%) |
241 (77%) |
160(78%) |
| LDH > ONW |
316 (23%) |
70 (23%) |
45(22%) |
| Bulky tumor (7.5 cm or larger) |
467 (33%) |
90 (29%) |
62(30%) |
Bittenbring et al. BMC Cancer 2008 8:116 doi:10.1186/1471-2407-8-116 |
|||